Trial Profile
Viral failure in patients living with HIV who treated with dolutegravir-based regimens versus other INSTI, and darunavir-based regimens
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 May 2019
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Darunavir; Integrase inhibitors
- Indications HIV infections
- Focus Therapeutic Use
- 29 Apr 2019 Results (n=5177) comparing regimen switching and virologic failure rates among people living with HIV who initiated recommended regimens in clinical care published in the JAIDS
- 27 Oct 2017 Results (n=1373) comparing outcomes among persons living with HIV initiating Dolutegravir based vesrsus other recommended regimens, presented at the 16th European AIDS Conference.
- 25 Oct 2017 New trial record